AVATROMBOPAG

Details

Stereochemistry	ACHIRAL
Molecular Formula	C29H34Cl2N6O3S2
Molecular Weight	649.655
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1CCN(CC1)C2=NC=C(C=C2Cl)C(=O)NC3=NC(C4=CC(Cl)=CS4)=C(S3)N5CCN(CC5)C6CCCCC6

InChI

InChIKey=OFZJKCQENFPZBH-UHFFFAOYSA-N

InChI=1S/C29H34Cl2N6O3S2/c30-20-15-23(41-17-20)24-27(37-12-10-35(11-13-37)21-4-2-1-3-5-21)42-29(33-24)34-26(38)19-14-22(31)25(32-16-19)36-8-6-18(7-9-36)28(39)40/h14-18,21H,1-13H2,(H,39,40)(H,33,34,38)

HIDE SMILES / InChI

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf | https://www.fiercepharma.com/pharma/dova-s-oral-platelet-booster-doptelet-approved-by-fda-shionogi-s-rival-closely-behind

Avatrombopag is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production. Avatrombopag was discovered by Yamanouchi Pharmaceutical, developed by AkaRx which late became acquired by Dova Pharmaceuticals. In 2018 avatrombopag was approved by the FDA for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Thrombopoietin receptor 8 Target ID: P40238 Gene ID: 4352.0 Gene Symbol: MPL Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19183407	Agonist 2678		3.3 nM [EC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic liver disease-associated thrombocytopenia 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf	Primary		Approved 8429	DOPTELET Approved Use Treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. Launch Date 2018

C_max

Value	Dose	Analyte	Population
284 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28339166/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	AVATROMBOPAG plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
388 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30203841	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	AVATROMBOPAG plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
95.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28339166/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	AVATROMBOPAG plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
117 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28339166/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	AVATROMBOPAG plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
183 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28339166/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	AVATROMBOPAG plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
164 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28339166/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	AVATROMBOPAG plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
10000 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28339166/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	AVATROMBOPAG plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
10863.5 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30203841	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	AVATROMBOPAG plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3160 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28339166/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	AVATROMBOPAG plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
3340 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28339166/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	AVATROMBOPAG plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4840 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28339166/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	AVATROMBOPAG plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5900 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28339166/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	AVATROMBOPAG plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
18.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28339166/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	AVATROMBOPAG plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
18 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30203841	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	AVATROMBOPAG plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
18.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28339166/	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:	AVATROMBOPAG plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
18 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28339166/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:	AVATROMBOPAG plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED

Doses

Dose	Population	Adverse events
100 mg single, oral Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: https://pubmed.ncbi.nlm.nih.gov/30203841	healthy, 25.5 years n = 6 Health Status: healthy Age Group: 25.5 years Sex: M+F Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/30203841	Other AEs: Dysgeusia, Flatulence... Other AEs: Dysgeusia (16.7%) Flatulence (16.7%) Dizziness (16.7%) Headache (16.7%) Diarrhoea (16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/30203841
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf	unhealthy, 58 years (range: 19-86 years) n = 115 Health Status: unhealthy Condition: thrombocytopenia Age Group: 58 years (range: 19-86 years) Sex: M+F Population Size: 115 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf	Other AEs: Pyrexia, Abdominal pain... Other AEs: Pyrexia (8%) Abdominal pain (7%) Nausea (7%) Headache (7%) Fatigue (3%) Edema peripheral (4%) Hyponatremia (serious, 8%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
60 mg 1 times / day multiple, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf	unhealthy, 58 years (range: 19-86 years) n = 159 Health Status: unhealthy Condition: thrombocytopenia Age Group: 58 years (range: 19-86 years) Sex: M+F Population Size: 159 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf	Disc. AE: Anemia, Pyrexia... Other AEs: Pyrexia, Abdominal pain... AEs leading to discontinuation/dose reduction: Anemia (0.4%) Pyrexia (0.4%) Myalgia (0.4%) Other AEs: Pyrexia (11%) Abdominal pain (6%) Nausea (6%) Headache (4%) Fatigue (4%) Edema peripheral (3%) Hyponatremia (serious, 7%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210238s000lbl.pdf
60 mg 1 times / day multiple, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf	unhealthy, 58 years (range: 19-86 years) n = 115 Health Status: unhealthy Condition: thrombocytopenia Age Group: 58 years (range: 19-86 years) Sex: M+F Population Size: 115 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf	Other AEs: Gastrointestinal disorders, General disorders and administration site conditions... Other AEs: Gastrointestinal disorders (25.2%) General disorders and administration site conditions (14.8%) Nervous system disorders (7.8%) Injury, poisoning and procedural complications (2.6%) Infection (9.6%) Infestation (9.6%) Respiratory disorder (8.7%) Thoracic disorders (excl lung and pleura) (8.7%) Mediastinal disorders (8.7%) Musculoskeletal disorder (5.2%) Connective tissue disorders (5.2%) Metabolism disorders NEC (5.2%) General nutrition disorder (5.2%) Skin disorder (1.7%) Skin and subcutaneous tissue disorders (1.7%) Blood disorder (3.5%) Lymphatic system disorders NEC (3.5%) Psychiatric disorders (4.3%) Urinary tract disorder NOS (3.5%) Renal disorder (3.5%) Vascular disorders (0.9%) Hepatobiliary disorders (1.7%) Eye disorders (0.9%) Cardiac disorders (0.9%) Disorder ear (0.9%) Labyrinthine disorders (0.9%) Endocrine disorders (0.9%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf
60 mg 1 times / day multiple, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf	unhealthy, 58 years (range: 19-86 years) n = 159 Health Status: unhealthy Condition: thrombocytopenia Age Group: 58 years (range: 19-86 years) Sex: M+F Population Size: 159 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf	Other AEs: Gastrointestinal disorders, General disorders and administration site conditions... Other AEs: Gastrointestinal disorders (29.6%) General disorders and administration site conditions (23.9%) Nervous system disorders (8.8%) Injury, poisoning and procedural complications (10.1%) Infection (3.1%) Infestation (3.1%) Respiratory disorder (4.4%) Thoracic disorders (excl lung and pleura) (4.4%) Mediastinal disorders (4.4%) Musculoskeletal disorder (6.9%) Connective tissue disorders (6.9%) Metabolism disorders NEC (3.8%) General nutrition disorder (3.8%) Skin disorder (5%) Skin and subcutaneous tissue disorders (5%) Blood disorder (3.8%) Lymphatic system disorders NEC (3.8%) Psychiatric disorders (3.1%) Urinary tract disorder NOS (1.3%) Renal disorder (1.3%) Vascular disorders (2.5%) Hepatobiliary disorders (1.9%) Eye disorders (2.5%) Cardiac disorders (0.6%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
	substrate 1037 inhibitor 1767 inducer 389	inhibitor 1852	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
BCRP 699 OAT3 642 CYP1A 72 CYP2B6 810 CYP2C8 911 CYP2C19 1478 CYP2E1 882 CYP3A 214 OAT1 599 OCT2 647 OATP1B1 788 OATP1B3 706	CYP3A 191 P-gp 1537 BCRP 561 OATP1B1 406 OATP1B3 350 OAT1 326 OAT3 339 OCT2 355 MATE1 135 MATE2 96	CYP2C8 168 CYP1A2 701 CYP2B6 547 CYP3A 129

Drug as perpetrator

Target	Modality	Activity
CYP1A 121	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	no
CYP1A2 1692	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	no
CYP2B6 1001	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	no
CYP2B6 1001	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	no
CYP2C19 1553	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	no
CYP2C8 965	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	no
CYP2C9 1819	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	no
CYP2D6 1891	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	no
CYP2E1 970	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	no
CYP3A 298	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	no
CYP3A 298	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	no
OAT1 603	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	no
OATP1B1 803	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	no
OATP1B3 715	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	no
OCT2 648	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	no
CYP2C8 965	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	weak
CYP2C9 1819	inducer 1573 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	weak
BCRP 773	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	yes
OAT3 644	inhibitor 3277 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=65 Page: 65.0	yes

Drug as victim

Target	Modality	Activity
CYP2C9 1037	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=64 Page: 64.0	major
CYP3A 191	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=64 Page: 64.0	major
BCRP 561	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=67 Page: 67.0	no
MATE1 135	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=67 Page: 67.0	no
MATE2 96	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=67 Page: 67.0	no
OAT1 326	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=67 Page: 67.0	no
OAT3 339	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=67 Page: 67.0	no
OATP1B1 406	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=67 Page: 67.0	no
OATP1B3 350	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=67 Page: 67.0	no
OCT2 355	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=67 Page: 67.0	no
P-gp 1537	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=67 Page: 67.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210238Orig1s000MultidisciplineR.pdf#page=36 Page: 36.0

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY561084	https://www.001chemical.com/chem/570406-98-3
AA Blocks	AA00ECCF	https://www.aablocks.com/goods/Goods/detail?id=AA00ECCF
Achemtek	0102-012478	http://www.achemtek.com/570406-98-3
Adooq BioScience	A14087	https://www.adooq.com/avatrombopag.html
Alfa Chemistry	570406-98-3	https://www.alfa-chemistry.com/akr-501-cas-570406-98-3-item-292701.htm
Angene	AGN-PC-0SMVXA	http://www.angenechemical.com/productshow/AGN-PC-0SMVXA.html
BioChemPartner	BCP28031	http://www.biochempartner.com/570406-98-3-BCP28031
Chem Scene	CS-3397	http://www.chemscene.com/570406-98-3.html
Chemspace	CSSS00015191580	https://chem-space.com/CSSS00015191580
Debye Scientific	DB-072238	http://www.debyesci.com/cas_570406-98-3.html
Finetech	FT-0728753	http://www.finetechnology-ind.com/prod/detail/pub/570406-98-3.html
Lab Network	LN01341838	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01341838
Matrix Scientific	148389	https://www.matrixscientific.com/148389.html
MedChem Express	HY-13463	https://www.medchemexpress.com/avatrombopag.html
Molcore	MC561084	https://www.molcore.com/product/570406-98-3
Selleck Chemicals	S6624	http://www.selleckchem.com/products/avatrombopag.html
Smolecule	S519822	http://www.smolecule.com/products/s519822
Synblock Inc	SB16846	http://www.synblock.com/product/570406-98-3.html
THE BioTek	bt-261048	https://www.thebiotek.com/product/inhibitors/bt-261048
eNovation Chemicals	D672684	https://www.enovationchem.com/ProductDetails.asp?ProductID=D672684
eNovation Chemicals	Y1084033	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1084033

PubMed

Title	Date	PubMed
AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis.	2008 Oct	18619724
AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist.	2009 Apr	19183407
Romiplostim: a second-generation thrombopoietin agonist.	2009 Mar	19436840

Patents

Sample Use Guides

In Vivo Use Guide

For patients with a platelet count 40000 to <50000/mm3: 40 mg once daily for 5 consecutive days, orally. For patients with platelet count below 40,000/mm3: 60 mg once daily for 5 consecutive days.

Route of Administration: Oral

In Vitro Use Guide

Avatrombopag stimulated the proliferation of cells expressing the human thrombopoietin receptor (c-Mpl) with an EC50 value of 3.3 nM and promoted the differentiation of human hematopoietic progenitor cells (cord blood CD34+ cells) to megakaryocytes with an EC50 value of 25.0 nM.

Name

Type

Language

AVATROMBOPAG

Official Name

English

YM-301477

Code

English

avatrombopag [INN]

Common Name

English

AKR-501

Common Name

English

YM-477

Code

English

AVATROMBOPAG [USAN]

Common Name

English

Avatrombopag [WHO-DD]

Common Name

English

E5501

Code

English

E-5501

Code

English

AVATROMBOPAG [MI]

Common Name

English

1-(3-Chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl}pyridin-2-yl)piperidine-4-carboxylic acid

Systematic Name

English

1-(3-CHLORO-5-((4-(4-CHLOROTHIOPHEN-2-YL)-5-(4-CYCLOHEXYLPIPERAZIN-1-YL)THIAZOL-2-YL)CARBAMOYL)-2-PYRIDYL)PIPERIDINE-4-CARBOXYLIC ACID

Systematic Name

English

Classification Tree Code System Code

WHO-ATC

B02BX08